

line 12, change "Panel A" to --Figure 4A(i)--, change "and" to --;
Figure 4A(ii);--;

line 13, change "B and C;" to --Figures 4B(i) and 4C(i);--;

line 14, before "Radioactivity", insert --Figures 4B(ii) and 4C(ii);-- and
change "D;" to --Figure 4D;--;

line 21, change "Fig. 6" to --Figures 6A to 6H--;

On page 15, line 6, change "Fig. 7" to --Figures 7A to 7C--;

line 7, change "Panel A" to --Figure 7A--;

line 13, change "B" to --Figure 7B--;

line 17, change "C" to --Figure 7C--;

line 20, change "A and C" to --Figures 7A and 7C--.

On page 20, line 13, following the sequence, insert --(SEQ ID NO:5)--

IN THE CLAIMS:

Please cancel claims 7-10, without prejudice or disclaimer, and enter the
following claims 12-20:

--12. Polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with
glucosyltransferase activity, consisting essentially of approximately the first 1020
amino acids (from the N-terminus on) of the amino acid sequence of *Clostridium*
sordellii lethal Toxin (LT) or a part thereof having a glucosyltransferase activity.

13. Immunotoxin with glucosyltransferase activity comprising (i) a
polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with
glucosyltransferase activity, consisting essentially of approximately the first 1020
amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) or

a part thereof having a glucosyltransferase activity, and (ii) a target cell specific binding domain, which domain causes the immunotoxin to bind to a target cell.

14. Immunotoxin comprising (i) a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with glucosyltransferase activity, consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) or a part thereof having a glucosyltransferase activity, (ii) a translocation domain for translocating the catalytic polypeptide from the exterior of a cell into the interior of said cell, and (iii) a target cell specific binding domain, which domain causes the immunotoxin to bind to a target cell.

15. Immunotoxin according to claim 14, wherein the translocation domain consists essentially of approximately the amino acids 1021-1700 (from the N-terminus on) of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT).

16. Immunotoxin according to one of claims 13 to 15, wherein the target cell specific binding domain is an antibody or an antigen binding fragment thereof.

17. A composition for treating a pathological condition in a patient involving activation of at least one Ras proto-oncoprotein, said composition comprising an immunotoxin according to one of claims 13 to 15 and a pharmaceutically acceptable adjuvant or carrier.

18. A composition for treating a pathological condition in a patient involving activation of at least one Ras proto-oncoprotein, said composition comprising an immunotoxin according to claim 16 and a pharmaceutically acceptable adjuvant or carrier.

19. A method of manufacturing a therapeutic composition, said method comprising the steps of bringing together an immunotoxin according to one of claims 13 to 15 and a pharmaceutically acceptable adjuvant or carrier.